Global Exogenous Circular RNA Synthesis Service Market Strategic Research Report

Scope of the Report

The global Exogenous Circular RNA Synthesis Service market size is predicted to grow from US$ 42.06 million in 2025 to US$ 218 million in 2032; it is expected to grow at a CAGR of 26.2% from 2026 to 2032.

Exogenous circular RNA synthesis services refer to specialized technical services that produce artificial circular RNA outside living cells based on customer-provided or jointly optimized sequences. The workflow typically includes DNA template construction, in vitro transcription, precursor RNA circularization, purification, analytical testing, and optional lipid nanoparticle formulation and clinical-grade manufacturing. The delivered RNA has already formed a covalently closed circular structure before being introduced into cells, tissues, or living organisms. Major circularization routes include PIE self-splicing, modified scarless PIE methods, and T4 RNA ligase-mediated enzymatic ligation. Deliverables include research-grade circRNA samples, preclinical drug substance, formulated samples, process-development packages, and GMP-compliant clinical batches. Upstream inputs mainly include nucleotide triphosphates, modified nucleosides, DNA and plasmid templates, RNA polymerases, RNA ligases, ribozyme elements, nucleases, buffers, chromatography media, ultrafiltration consumables, single-use bioprocessing materials, analytical reagents, and lipid materials. Downstream customers primarily include RNA drug developers, vaccine companies, gene and cell therapy companies, pharmaceutical companies, universities, research institutes, and hospital research centers. Pricing is generally determined by sequence length, delivery scale, circularization method, purity grade, analytical requirements, formulation needs, and quality-system requirements. Research-grade projects are usually priced by sequence and quantity, while clinical and industrial projects are priced through process-development and batch-manufacturing contracts. The industry's overall gross margin in 2025 is estimated at approximately 40%–60%.

The exogenous circular RNA synthesis services market is still dominated by research-grade and preclinical projects, although customer demand is expanding from basic circRNA sample preparation to sequence optimization, circularization screening, impurity removal, analytical method development, and delivery formulation. Early suppliers mainly delivered microgram- to milligram-scale research samples, while several integrated service providers have developed larger-scale production, LNP formulation, and clinical-grade quality systems. Global supply is concentrated mainly in China and the United States. Chinese providers have developed broad capabilities in circularization processes, research services, and integrated CRDMO support, while U.S.-based providers generally benefit from international customer coverage, standardized service models, and established nucleic acid development infrastructure. The market remains characterized by a limited supplier base, highly customized projects, and revenues concentrated in the development stage.

Future competition will shift from basic circularization capability toward high purity, scarless products, long-sequence compatibility, low immunogenicity, and reproducible scale-up. Conventional PIE methods have a relatively established application base but may face challenges involving junction scars, sequence restrictions, and by-product control. Modified scarless PIE and ligase-based approaches offer greater sequence flexibility but impose additional requirements on terminal structure, splint design, enzyme cost, and downstream purification. As customer programs enter clinical development, residual linear RNA, double-stranded RNA, truncated transcripts, free intron fragments, and residual DNA will become increasingly important quality attributes. Suppliers with proprietary analytical methods and biological potency testing capabilities will gain a stronger competitive position.

Market growth is being driven by expanding development activity in circular RNA therapeutics, therapeutic vaccines, protein-expression therapies, in vivo cell therapies, and gene-editing research. Compared with building internal in vitro transcription and circularization platforms, outsourcing gives developers access to validated templates, circularization elements, purification processes, and analytical systems, reducing development risk and shortening timelines to animal studies and regulatory submissions. As programs move from discovery to preclinical and clinical stages, additional testing for circularization efficiency, purity, integrity, residual DNA, double-stranded RNA, endotoxin, sterility, and potency expands the service scope and contract value. Providers offering integrated template production, circRNA drug substance, LNP formulation, and quality studies will be better positioned to secure long-term projects.

The main barriers are the lack of harmonized quality and regulatory standards and differences in how suppliers measure circularization efficiency, purity, integrity, and expression activity. A high apparent circularization rate does not necessarily indicate high functional purity, because mis-ligated products, uncircularized precursors, double-stranded RNA, and truncated transcripts may affect expression and immune responses. Long-sequence circularization efficiency, purification recovery, and batch consistency remain technical challenges. Clinical-grade production also involves significant costs related to high-grade raw materials, quality validation, facility maintenance, and regulatory documentation. Because the number of clinical-stage exogenous circRNA programs remains limited, GMP capacity utilization and order continuity also constrain the stability of supplier profitability.

This report presents a comprehensive overview of the global Exogenous Circular RNA Synthesis Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Custom Synthesis
• Process Development
• Analytical and QC Services
• Other

Segment by Circularization Method

• PIE Circularization
• Enzymatic Ligation
• Other

Segment by Product Format

• Naked circRNA
• circRNA-LNP
• Other

Segment by Application

• Pharmaceutical and Biotechnology Companies
• CRO and CDMO Companies
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Exogenous Circular RNA Synthesis Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical and Biotechnology Companies, CRO and CDMO Companies, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact